Delivery Order SPE2DB24D8001-SPE2DB25FKZSN
Award Date
5/15/25
Potential Completion Date
5/16/25
Potential Value
$5K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award by the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense, to Dakota Drug, Inc., a self-certified small disadvantaged business. The $6,953.97 Firm Fixed Price delivery order contract is for the provision of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a pharmaceutical product. The contract has an ultimate completion date of October 25, 2023 and is not associated with a set-aside program. Dakota Drug, Inc. holds a significant single-award...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $1,571.74, is for the delivery of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML pharmaceutical products. The contract has an ultimate completion date of January 14, 2025 and is part of the DLA Troop Support Medical's ECAT Generation V Program, a large indefinite delivery contract (IDC) that allows Dakota Drug, Inc. to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a prescription medication. The contract, valued at $1,863.70, has an ultimate completion date of August 29, 2024. Dakota Drug, Inc. is an experienced prime contractor to the DLA Troop Support Medical, providing a wide range of pharmaceutical products, medical supplies, and healthcare...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $2,489.36, is for the delivery of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a pharmaceutical product. The contract is part of the DLA Troop Support Medical's ECAT Generation V Program, an Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that allows Dakota Drug, Inc. to provide a wide range of pharmaceutical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML. The single-award Indefinite Delivery Contract (IDC) has a ceiling value of $1,571.74 and a performance period extending through March 4, 2025. This contract is part of the DLA Troop Support Medical's ECAT Generation V Program, which enables Dakota Drug, Inc. to efficiently deliver a comprehensive range of...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract, valued at $7,387.40, is for the delivery of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a biologic drug used to treat autoimmune conditions. The contract has an ultimate completion date of May 21, 2024 and was awarded on May 20, 2024 without any set-aside...
This federal contract award, valued at $2,595.91, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc. The contract is a firm fixed-price delivery order for the pharmaceutical product ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML. Dakota Drug, Inc. is a self-certified small disadvantaged business operating as a for-profit subchapter S corporation that specializes in providing pharmaceutical products, medical supplies, and healthcare equipment to the U.S. federal...
This federal contract award, identified as SPE2DX15D8001|SPE2DX24FBPWS, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a pharmaceutical product, with a ceiling value of $3,267.50. The contract has an ultimate completion date of October 16, 2023 and was awarded on October 13, 2023. This award is not associated with a set-aside program,...
This is a $2,732.81 firm fixed-price delivery order award to Dakota Drug, Inc., a self-certified small disadvantaged business, by the Defense Logistics Agency (DLA) Troop Support Medical division. The award is for the delivery of Actemra Actpen 162 mg/0.9 ml medication. Dakota Drug, Inc. holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, which enables the company to provide a wide range of pharmaceutical products,...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $4,904.78, is for the delivery of Actemra Actpen 162 mg/0.9 ml, a pharmaceutical product, to support U.S. Armed Forces medical operations. The contract is a Firm Fixed Price Delivery Order with a performance period ending on May 22, 2024. Dakota Drug, Inc. has a significant single-award Indefinite Delivery Contract (IDC) with the...